GlassScriptPhysician profile
Kerney Yu
NPI 1386206712
$3,983.33
in general payments reported to CMS, 2019-2025
34 companies · $22.37 in 2025
The $22.37 reported for 2025 was less than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $3,048 · 2022: $813 · 2023: $99.98 · 2025: $22.37.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $122.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $122.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $695.08 | 2021-2023 | |
| Novo Nordisk INC | $567.36 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $376.50 | 2021-2023 | Breztri |
| Lilly USA, LLC | $291.14 | 2021-2022 | |
| Esperion Therapeutics, INC. | $242.79 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $210.22 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $205.09 | 2021 | |
| Amarin Pharma, INC. | $146.73 | 2021-2022 | |
| Glaxosmithkline, LLC. | $134.27 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $123.79 | 2021 | |
| Amgen INC. | $90.26 | 2021-2022 | |
| Pfizer INC. | $89.04 | 2021-2023 | |
| Biohaven Pharmaceuticals, INC. | $88.29 | 2021 | |
| Astellas Pharma US INC | $85.00 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $84.59 | 2022 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch Health US, LLC | $67.47 | 2021 | |
| Nestle Healthcare Nutrition INC. | $63.87 | 2021 | |
| Jazz Pharmaceuticals INC. | $59.52 | 2021 | |
| Horizon Therapeutics Plc | $42.64 | 2022-2023 | Krystexxa |
| Sanofi-Aventis U.S. LLC | $36.28 | 2021 | |
| Eisai INC. | $34.14 | 2021 | |
| Abbott Laboratories | $30.91 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $25.40 | 2021 | |
| Idorsia Pharmaceuticals US INC | $23.59 | 2022 | |
| Organon LLC | $22.88 | 2022 | |
| Boston Scientific Corporation | $22.37 | 2025 | Wavewriter Alpha Prime 16 |
| Lundbeck LLC | $19.75 | 2022 | |
| Janssen Pharmaceuticals, INC | $19.06 | 2022 | |
| Novartis Pharmaceuticals Corporation | $15.70 | 2022 | |
| Sunovion Pharmaceuticals INC. | $15.61 | 2021 | |
| Adlon Therapeutics L.P. | $15.04 | 2021 | |
| Clarus Therapeutics INC. | $14.10 | 2021 | |
| Vivus LLC | $13.17 | 2021 | |
| Arbor Pharmaceuticals, INC. | $11.68 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kerney Yu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.